Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.
Abstract readClinical Trial, Phase IIIMulticenter Study
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 2 pooled it
15.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 2 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.The Cochrane database of systematic reviews · 2023Pooled it
- A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer.Scientific reports · 2021Trial
- Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.Gynecologic oncology · 2019Trial
- Age as a biological stratifier for immune checkpoint inhibitor response in ovarian cancer.Research square · 2026Article
- The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Transcriptome signatures for the identification of bevacizumab responders in ovarian cancer.Genome medicine · 2026Article
- Immunological and prognostic impact of NRF2 in high grade serous ovarian cancer.Genes and immunity · 2026Article
- Article
- Rethinking ovarian cancer III: the past decade and future directions.Nature reviews. Cancer · 2026Review
- Spliceosomal component SNRPE drives cell proliferation by regulating CTP synthase 1 mRNA splicing in ovarian cancer.Oncogene · 2026Article
- Development and validation of a macrophage-related prognostic model for overall survival in ovarian cancer via integrated RNA sequencing analysis.Translational cancer research · 2026Article
- Identification and validation of a sphingolipid metabolism-related prognostic signature for predicting prognosis and immune microenvironment-related characteristics in ovarian cancer.Translational cancer research · 2026Article
- S100B induces angiogenesis via the clathrin/FOXO1/β-catenin signaling pathway and contributes to Bevacizumab resistance in epithelial ovarian cancer.Journal of advanced research · 2026Article
- High-grade serous ovarian cancer induced in different sites of origin in mice exemplifies diverse features of the human disease.iScience · 2026Article
- Multimodal-based analysis of single-cell ATAC-seq data enables highly accurate delineation of clinically relevant tumor cell subpopulations.Genome medicine · 2026Article
- PRECOG update: an augmented resource of clinical outcome associations with gene expression for adult, pediatric, and immunotherapy cohorts.Nucleic acids research · 2026Article
- A Novel Partial EMT-Associated Transcriptomic Signature for Prognostic Stratification in Ovarian Cancer.Oncology research · 2026Article
- Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial.NPJ precision oncology · 2025Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 19 institutions in 3 countries.
Stefan KommossDepartment of Women's Health, Tuebingen University Hospital, Tuebingen, Germany.
Boris WinterhoffDivision of Gynecologic Surgery, Mayo Clinic, Minnesota.
Ann L ObergDepartment of Health Sciences Research, Mayo Clinic, Minnesota.
Gottfried E KonecnyDivision of Medical Oncology, UCLA, California.
Chen WangDepartment of Health Sciences Research, Mayo Clinic, Minnesota.
Shaun M RiskaDepartment of Health Sciences Research, Mayo Clinic, Minnesota.
Jian-Bing FanAnchorDx Corporation, Guangzhou, China.
Matthew J MaurerDepartment of Health Sciences Research, Mayo Clinic, Minnesota.
Craig AprilIllumina Inc., San Diego, California.
Viji ShridharDepartment of Laboratory Medicine, Mayo Clinic, Minnesota.
Friedrich KommossInstitute of Pathology, Mannheim, Germany.
Andreas du BoisKliniken Essen Mitte (KEM), Deptartment of Gynecology and GynecologicOncology, Essen, Germany.
Felix HilpertDepartment of Gynecology and Obstetrics, Schleswig-Holstein University, Kiel, Germany.
Sven MahnerDepartment of Obstetrics and Gynecology, Ludwig Maximillian University Munich, Germany.
Klaus BaumannDepartment of Gynecology and Gynecologic Oncology, Philipps University Marburg, Germany.
Willibald SchroederGynaecologicum Bremen, Bremen, Germany.
Alexander BurgesKlinikum der Universitaet Muenchen, Campus Grosshadern, Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe, Munich, Germany.
Ulrich CanzlerDepartment of Gynecology and Obstetrics, Technical University Dresden, Dresden, Germany.
Jeremy ChienDepartment of Cancer Biology, University of Kansas Cancer Center, Kansas City, Kansas.
Andrew C EmbletonMedical Research Council Clinical Trials Unit at University College London, UK.
Mahesh ParmarMedical Research Council Clinical Trials Unit at University College London, UK.
Richard KaplanMedical Research Council Clinical Trials Unit at University College London, UK.
Timothy PerrenLeeds Institute of Cancer Medicine and Pathology, University of Leeds, UK.
Lynn C HartmannDivision of Medical Oncology, Mayo Clinic, Minnesota.
Ellen L GoodeDepartment of Health Sciences Research, Mayo Clinic, Minnesota.
Sean C DowdyDivision of Gynecologic Surgery, Mayo Clinic, Minnesota. dowdy.sean@mayo.edu.
Jacobus PfistererGynecologic Oncology Center, Kiel, Germany.
Mayo Clinic Health System · USMRC Clinical Trials Unit at UCL · GBIllumina (United States) · USMayo Clinic · USGynecologic Oncology Group · USKliniken Essen-Mitte · DEKlinik für Frauenheilkunde · DELudwig-Maximilians-Universität München · DEMayo Clinic in Arizona · USPhilipps University of Marburg · DETechnische Hochschule Mannheim · DETechnische Universität Dresden · DEThe University of Kansas Cancer Center · USUCLA Medical Center · USUniversity Children's Hospital Tübingen · DEUniversity Hospital Schleswig-Holstein · DEUniversity of Bremen · DEUniversity of Leeds · GBUniversity of Minnesota · US
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0MMedical Research Council MC_UU_12023/20NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA136393
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overBevacizumabBiomarkers, TumorCell ProliferationDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedOvarian NeoplasmsTreatment OutcomeBevacizumabBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.